During the corresponding time, Science 37 Holdings Inc saw a revenue deteriorated by -8.38 % year on year, sequentially revenue fell by -3.02 %. While revenue at the Science 37 Holdings Inc 's corporate clients
The landscape of clinical trials is undergoing a transformative shift fueled by innovative digital strategies. This change is exemplified by Science 37 s remarkable contribution to GlaxoSmithKline s (GSK) Phase 3 rare disease trial. Recent announcements reveal that Science 37 nearly doubled the U.S. enrollment and contributed almost half of the participants in this critical study. This article delves into the facts surrounding this achievement and examines the potential ramifications for Science 37 s standing in the clinical trial industry. Science 37 s Role in GSK s Phase 3 Rare Disease Trial Science 37, a leader in decentralized clinical trials, has leveraged its platform to significantly enhance participa...
In a significant milestone for the decentralized clinical trials (DCT) landscape, Science 37 has been awarded the 2024 Global Company of the Year Award by Frost and Sullivan. This honor not only underscores Science 37’s position as an industry leader but also highlights the growing importance of decentralized methodologies in clinical research. The award recognizes key attributes of Science 37, namely its visionary innovation, market-leading performance, and unmatched customer care, all of which are driving transformative changes in how clinical trials are conducted.The DCT model, which leverages technology to decentralize traditional clinical trial processes, has gained traction amid the shifting dynamics...
In an era where medical research and innovation are vital for advancing healthcare, clinical trials play a crucial role in bringing new therapies and treatments to patients. One persistent challenge in conducting clinical trials has been the slow recruitment and enrollment of participants. However, Science 37, a pioneering company, has emerged as a game-changer in this aspect, providing innovative solutions to expedite these critical processes. With their exceptional medical expertise and operational efficiency, Science 37 has successfully boosted patient recruitment in under-enrolling clinical trials, revolutionizing the landscape of medical research.Science 37, a decentralized clinical trial software platf...
Clinical trials are vital for advancing medical knowledge and developing new treatments for various diseases. However, traditional trial structures often face challenges, particularly in enrolling patients with rare diseases who are geographically dispersed and face limited access to specialized healthcare centers. This article explores how Science 37, an innovative clinical research company, has successfully addressed these issues by surpassing enrollment goals and accelerating Phase 2 rare disease trials. By adopting a patient-centric approach and leveraging technology, Science 37 has revolutionized the landscape of clinical research, facilitating breakthroughs for patients with rare diseases.Enhancing Pat...
In the race to develop groundbreaking medical treatments, clinical trials play a crucial role in assessing the effectiveness and safety of new therapies. However, one of the biggest challenges faced by researchers is ensuring a sufficient number of participants for these trials. To address this issue, Science 37 has developed an innovative patient recruitment solution that supplies fully-consented patients to clinical trial sites, thereby supplementing enrollment and accelerating the progress of medical research.Clinical trials serve as critical gateways for new medications and treatments to reach the public, and a lack of participants can significantly hinder the speed at which these trials can be completed...
Science 37 Holdings, Inc., a leading Metasite company, recently announced the granting of inducement equity awards under their Employment Inducement Incentive Award Plan. This move indicates the company s commitment to attracting and retaining top talent and highlights its sustained growth in the industry. In this article, we will outline the key facts surrounding this announcement and assess its potential impact on Science 37 Holdings, Inc. Facts: 1. Granting of Inducement Equity Awards: Science 37 Holdings, Inc. approved the granting of inducement equity awards under their Employment Inducement Incentive Award Plan. This plan was endorsed by the company s Board of Directors in November 20...
Sources:
Science 37 Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Science 37 Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Science 37 Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
